LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Elenco Azioni・Coherus Oncology Inc

Search

Coherus Oncology Inc

Chiusa

SettoreSettore sanitario

1.36 -6.21

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.34

Massimo

1.44

Metriche Chiave
By Trading Economics
Entrata	-278M -37M
Vendite	-438K 12M
P/E Media del settore	3.509 49.052
EPS	-0.25
Margine di Profitto	-300.041
Dipendenti	145
EBITDA	7.9M -35M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+480.99% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-40M 219M
Apertura precedente	7.57
Chiusura precedente	1.36

Notizie sul Sentiment di mercato

By Acuity

50%

50%

154 / 344 Classifica in Healthcare

Coherus Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 giu 2026, 23:36 UTC

Utili

Correction to Oracle Reports Higher 4Q Profit Article

10 giu 2026, 23:19 UTC

Azioni calde

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

10 giu 2026, 23:09 UTC

I principali Market Mover

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

10 giu 2026, 23:04 UTC

Utili

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

10 giu 2026, 20:44 UTC

I principali Market Mover

Caterpillar Raises Quarterly Dividend 8%

10 giu 2026, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Northern Star Should Take No Options Off The Table

10 giu 2026, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

10 giu 2026, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

10 giu 2026, 23:47 UTC

Discorsi di Mercato

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

10 giu 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

10 giu 2026, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

10 giu 2026, 23:32 UTC

Discorsi di Mercato

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

10 giu 2026, 23:20 UTC

Discorsi di Mercato

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

10 giu 2026, 22:05 UTC

Discorsi di Mercato

Correction to Bank of Canada Stays on Hold Market Talk

10 giu 2026, 21:57 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 giu 2026, 21:52 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 giu 2026, 21:35 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 giu 2026, 21:22 UTC

Utili

Oracle Stock Slides on Increased Capital Spending -- WSJ

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Utili

Tech, Media & Telecom Roundup: Market Talk

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

10 giu 2026, 20:39 UTC

Discorsi di Mercato

Utili

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

10 giu 2026, 20:34 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

10 giu 2026, 20:33 UTC

Utili

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

10 giu 2026, 20:33 UTC

Discorsi di Mercato

Utili

Global Equities Roundup: Market Talk

10 giu 2026, 20:33 UTC

Discorsi di Mercato

Utili

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

Confronto tra pari

Modifica del prezzo

Coherus Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

480.99% in crescita

Previsioni per 12 mesi

Media 8.25 USD 480.99%

Alto 12 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

154 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Altri titoli del settore

LLY

Eli Lilly and Co.

1,136.41

JNJ

Johnson and Johnson

238.85

ABBV

AbbVie Inc

225.29

UNH

UnitedHealth Group Inc

407.06

MRK

Merck & Co Inc.

119

Live chat